EFONIDIPINE CAS 111011-76-8 for Hypertension Treatment

Product Description:

Product Name: EFONIDIPINE CAS NO: 111011-76-8

Synonyms:

Efonidipine hydrochloride monoethanolate;

2-(phenyl(phenylmethyl)amino)ethyleste;

3-pyridinecarboxylicacid,1,4-dihydro-2,6-dimethyl-5-(5,5-dimethyl-1,3,2-dioxa;

Chemical & Physical Properties:

Appearance: Yellow powder

Assay :≥99.00%

Density: 1.3g/cm3

Boiling Point: 746.9℃ at 760mmHg

Flash Point: 405.5℃

Vapor Pressure: 3.5E-22mmHg at 25℃

Melting Point: 151° (dec)

Index of Refraction: 1.625

Storage Condition: Desiccate at +4℃

Efonidipine hydrochloride ethanol was first launched in Japan for the treatment of essential severe and renal hypertension. As the fourteenth dihydropyridine (DHP) calcium channel blocker to reach the market, it functions by binding to the DHP receptors on voltage-dependent calcium channels to cause diuretic and natriuretic actions in patients with essential hypertension. Its vasodilating and calcium antagonist effects are very slow in onset and long-lasting in all types of experimentally hypertensive models and the agent is reported to exhibit an improved side effect profile compared with other drugs of the same class. This may be explained by the slow and long-lasting inhibition of transmembrane Ca+2 uptake, which is accompanied by its very slow binding to and dissociation from the DHP receptors. A recent study in cholesterol-fed rabbits suggested that efonidipine may suppress the development of atherosclerosis without affecting the plasma lipids. Clinical trials for angina, peetoris, and for cerebrovasodilatory disorders have been reported.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.